(Q46669792)

24 December 2017

title

The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome (English)

1 reference

24 December 2017

polycystic ovary syndrome

main subject

patient

0 references

1 reference

1 reference

1 reference

1 reference

Murat Yilmaz

1

1 reference

24 December 2017

Neslihan Bukan

2

1 reference

24 December 2017

Göksun Ayvaz

3

1 reference

24 December 2017

Ayhan Karakoç

4

1 reference

24 December 2017

Füsun Törüner

5

1 reference

24 December 2017

Nuri Cakir

6

1 reference

24 December 2017

Metin Arslan

7

1 reference

24 December 2017

language of work or name

English

0 references

publication date

25 August 2005

1 reference

24 December 2017

published in

Human Reproduction

1 reference

24 December 2017

volume

20

1 reference

24 December 2017

issue

12

1 reference

24 December 2017

page(s)

3333-3340

1 reference

24 December 2017

Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase

cites work

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Superoxide dismutase, catalase and glutathione peroxidase activities in human blood: influence of sex, age and cigarette smoking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Diabetes mellitus: oxidative stress and wine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Is insulin resistance an essential component of PCOS?: The influence of confounding factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Hyperhomocysteinemia: a million ways to lose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Clinical assessment of body hair growth in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Plasma protein oxidation and antioxidant defense during aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Current views on the mechanism of action of thiazolidinedione insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Cardiovascular risk in women with polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Polycystic ovary syndrome and cardiovascular disease: a premature association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Oxidant stress: a key determinant of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

The plasma homocysteine levels are increased in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Decreased rate of coronary restenosis after lowering of plasma homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEI258

21 January 2018

Identifiers

DOI

10.1093/HUMREP/DEI258

1 reference

24 December 2017

1 reference

24 December 2017